News

According to Mersana, the studies showed that XMT-1107, a novel anti-angiogenic fumagillin analog conjugated to Mersana’s Fleximer, demonstrated superior anti-tumor activity in tumor xenograft models in comparison to

According to HST, this acquisition will allow the company to provide alternative healthcare options for those who are suffering from late stage cancer. Ron Howell, president and CEO

On April 17, 2009, CV Therapeutics merged with a wholly-owned subsidiary of Gilead. As a result of the merger, each outstanding share of CV Therapeutics not owned by

The new name reflects a major repositioning of the company to focus development activities on its drug candidate MIS416, which has shown promising activity in preclinical proof-of-principle studies

This includes full-scale commercial production capabilities, including dispensing, granulation, compression, film coating and primary packaging. The new area will utilize abatement technology, which is used for the elimination

StemCells, a clinical-stage biotechnology company, has granted a non-exclusive license for the company’s recently acquired internal ribosome entry site technology to a major international pharmaceutical company. According to

Under the terms of the agreement, Galapagos will receive an upfront fee of E2.5 million from Merck. In addition, Galapagos is eligible to receive discovery, development and regulatory

The gross proceeds to Hansen Medical, before expenses, from the sale of shares are expected to be $37.99 million. The closing of the offering is expected to take

Norway-based pharmaceutical company Clavis Pharma has initiated the first Phase II study with Intravenous CP-4126 in patients with newly diagnosed, advanced pancreatic cancer. Intravenous CP-4126 is a novel